211 related articles for article (PubMed ID: 27865832)
1. Establishment of monoclonal antibodies against cell surface domains of ASCT2/SLC1A5 and their inhibition of glutamine-dependent tumor cell growth.
Suzuki M; Toki H; Furuya A; Ando H
Biochem Biophys Res Commun; 2017 Jan; 482(4):651-657. PubMed ID: 27865832
[TBL] [Abstract][Full Text] [Related]
2. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
3. Target the human Alanine/Serine/Cysteine Transporter 2(ASCT2): Achievement and Future for Novel Cancer Therapy.
Jiang H; Zhang N; Tang T; Feng F; Sun H; Qu W
Pharmacol Res; 2020 Aug; 158():104844. PubMed ID: 32438035
[TBL] [Abstract][Full Text] [Related]
4. The role of the glutamine transporter ASCT2 in antineoplastic therapy.
Teixeira E; Silva C; Martel F
Cancer Chemother Pharmacol; 2021 Apr; 87(4):447-464. PubMed ID: 33464409
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.
Hara Y; Minami Y; Yoshimoto S; Hayashi N; Yamasaki A; Ueda S; Masuko K; Masuko T
Cancer Med; 2020 Jan; 9(1):302-312. PubMed ID: 31709772
[TBL] [Abstract][Full Text] [Related]
6. Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation.
Yu X; Plotnikova O; Bonin PD; Subashi TA; McLellan TJ; Dumlao D; Che Y; Dong YY; Carpenter EP; West GM; Qiu X; Culp JS; Han S
Elife; 2019 Oct; 8():. PubMed ID: 31580259
[TBL] [Abstract][Full Text] [Related]
7. Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening.
Colas C; Grewer C; Otte NJ; Gameiro A; Albers T; Singh K; Shere H; Bonomi M; Holst J; Schlessinger A
PLoS Comput Biol; 2015 Oct; 11(10):e1004477. PubMed ID: 26444490
[TBL] [Abstract][Full Text] [Related]
8. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
9. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
[TBL] [Abstract][Full Text] [Related]
10. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
[TBL] [Abstract][Full Text] [Related]
11. Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
Bröer A; Rahimi F; Bröer S
J Biol Chem; 2016 Jun; 291(25):13194-205. PubMed ID: 27129276
[TBL] [Abstract][Full Text] [Related]
12. Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter.
Bungard CI; McGivan JD
Biochem J; 2004 Aug; 382(Pt 1):27-32. PubMed ID: 15175006
[TBL] [Abstract][Full Text] [Related]
13. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
[TBL] [Abstract][Full Text] [Related]
14. Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds.
Ndaru E; Garibsingh RA; Shi Y; Wallace E; Zakrepine P; Wang J; Schlessinger A; Grewer C
J Gen Physiol; 2019 Mar; 151(3):357-368. PubMed ID: 30718375
[TBL] [Abstract][Full Text] [Related]
15. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
16. Cryo-EM structure of the human neutral amino acid transporter ASCT2.
Garaeva AA; Oostergetel GT; Gati C; Guskov A; Paulino C; Slotboom DJ
Nat Struct Mol Biol; 2018 Jun; 25(6):515-521. PubMed ID: 29872227
[TBL] [Abstract][Full Text] [Related]
17. 2-Substituted Nγ-glutamylanilides as novel probes of ASCT2 with improved potency.
Schulte ML; Dawson ES; Saleh SA; Cuthbertson ML; Manning HC
Bioorg Med Chem Lett; 2015 Jan; 25(1):113-6. PubMed ID: 25435145
[TBL] [Abstract][Full Text] [Related]
18. Ablation of the
Bröer A; Gauthier-Coles G; Rahimi F; van Geldermalsen M; Dorsch D; Wegener A; Holst J; Bröer S
J Biol Chem; 2019 Mar; 294(11):4012-4026. PubMed ID: 30635397
[TBL] [Abstract][Full Text] [Related]
19. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells.
Wang W; Pan H; Ren F; Chen H; Ren P
Biosci Rep; 2022 Mar; 42(3):. PubMed ID: 35237783
[TBL] [Abstract][Full Text] [Related]
20. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation.
Ren P; Yue M; Xiao D; Xiu R; Gan L; Liu H; Qing G
J Pathol; 2015 Jan; 235(1):90-100. PubMed ID: 25142020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
